DEERFIELD, Ill., Jan. 27, 2016 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., (Takeda) (TSE: 4502) today announced that the United States (U.S.) Food and Drug Administration (FDA) approved ...

TWi Pharmaceuticals, Inc. ("TWi") today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda ...

HAYWARD, Calif. — Generic drug maker Impax Labs is hoping to become the first to market a version of a gastroesophageal reflux disease treatment made by Takeda Pharmaceutical. Impax said Tuesday that ...

TAIPEI, April 27, 2015 /PRNewswire/ -- TWi Pharmaceuticals, Inc. ("TWi") today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda ...

DEERFIELD, Ill., Nov. 17, 2011 /PRNewswire/ -- Today, Takeda Pharmaceuticals North America, Inc., (Takeda) announced the DEXILANT (dexlansoprazole) product labeling now includes information from a ...

On January 23, 2023, the Federal Court released a decision by Associate Judge Tabib denying Takeda’s motion to consolidate two actions commenced under the Patented Medicines (Notice of Compliance) ...

Takeda Pharmaceuticals’ Dexilant SoluTab delayed-release orally disintegrating tablets received FDA approval. 1. The tablets are a new formulation of dexlansoprazole that can be taken by allowing the ...

NEW ORLEANS — Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals ...

Please provide your email address to receive an email when new articles are posted on . Takeda Pharmaceuticals announced the FDA has approved Dexilant for patients aged between 12 and 17 years with ...

Data results from a recent retrospective analysis of DEXILANT delayed release capsules and lansoprazole were presented at Digestive Disease Week (DDW) 2010 in New Orleans. DEXILANT is a proton pump ...

A drug company worker accusing his employer of encouraging excessive dosage in heartburn medication prescriptions faces a last-ditch fight at the U.S. Supreme Court—whose decision could dramatically ...